Direct-to-Consumer (DTC) Genetic Testing Global Market Report 2024

The direct-to-consumer (dtc) genetic testing market size has grown rapidly in recent years. It will grow from $1.57 billion in 2023 to $1.83 billion in 2024 at a compound annual growth rate (CAGR) of 16.6%. The growth observed in the historic period can be attributed to factors such as a growing curiosity about ancestry and heritage, trends in health and wellness, effective marketing and consumer education, concerns related to privacy and control over genetic data, and the increasing affordability and accessibility of genetic testing.

The direct-to-consumer (dtc) genetic testing market size is expected to see rapid growth in the next few years. It will grow to $3.32 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The anticipated growth in the forecast period can be attributed to factors such as the expansion of test offerings, integration with personalized medicine, collaborations with health and wellness industries, advancements in genetic research, and government support and regulations. Major trends expected in this period include the further expansion of test offerings and panels, educational initiatives for consumers, increased regulatory compliance and oversight, a focus on genomic data research and contributions, as well as efforts towards price reduction and enhanced accessibility.

The increasing incidence of diseases and disorders with genetic transmission capabilities is anticipated to fuel the expansion of the direct-to-consumer (DTC) genetic testing market in the future. Genetic disorders, characterized by mutations in an individual's DNA, encompass single-gene, multifactorial, and chromosomal disorders. Direct-to-consumer genetic testing plays a crucial role in raising awareness about various genetic disorders, facilitating predictions about health, and offering personalized insights into an individual's health, disease risks, and other traits. This, in turn, empowers individuals to make informed decisions regarding their health and lifestyle to mitigate disease risks. For example, as per MedlinePlus, a US-based online information service, syndrome A affects approximately 1 in 200,000 Americans annually, with around 100,000 children currently afflicted by syndrome B. Additionally, global statistics reveal that roughly 12,000 individuals succumbed to syndrome C in 2020, and disorder D develops in approximately 1% of the US population during their lifetimes. Furthermore, data from the World Health Organization (WHO) in February 2022 indicate that birth abnormalities lead to the annual demise of 240,000 newborns within the first 28 days of life and an extra 170,000 children aged 1 month to 5 years due to conditions such as heart defects, neural tube defects, and Down syndrome. Consequently, the escalating prevalence of genetically transmissible diseases and disorders is propelling the growth of the direct-to-consumer (DTC) genetic testing market.

The anticipated expansion of digital health solutions is set to drive the growth of the direct-to-consumer (DTC) genetic testing market in the foreseeable future. Digital health leverages technology to enhance healthcare, improve patient outcomes, streamline processes, and empower individuals in managing their health. DTC genetic testing plays a pivotal role in this digital health growth by actively engaging consumers, integrating genetic data for personalization, facilitating telehealth services, connecting with wearable devices, and advocating for preventive care. An example of this trend is highlighted in a September 2022 report from the American Medical Association, a US-based professional organization. The report reveals a significant increase in the percentage of physicians who perceive digital health tools as beneficial for patient care, rising from 85% in 2016 to 93% in 2022. Furthermore, the average number of digital health tools utilized by physicians has also witnessed a notable growth, increasing from 2.2 in 2016 to 3.8 in 2022. Consequently, the surge in digital health solutions is a driving force behind the growth of the direct-to-consumer (DTC) genetic testing market.

Major players in the direct-to-consumer (DTC) genetic testing market are placing a strategic emphasis on substantial investments in genetic research to maintain their market positions. These investments serve as crucial financial support for genetic testing companies, enabling them to engage in research initiatives, advance technologies, broaden market outreach, ensure regulatory compliance, and foster innovation. As an illustrative example, in November 2022, Redcliffe Labs, an India-based provider of diagnostic services and laboratories, disclosed its intention to allocate an additional $10 million (approximately Rs 81 crore) for the expansion of its genetic and specialized testing portfolio. This financial commitment aims to further enhance the company's capabilities in genetic testing, encompassing areas such as prenatal, oncology, neurology, nephrology, and pharmacogenomics. Notably, Redcliffe Labs has already invested $6 million in the coverage of genetics and specialized testing, emphasizing a forward-looking approach towards next-generation technologies within the diagnostics sector.

Major players in the direct-to-consumer (DTC) genetic testing market are actively engaging in strategic collaborations to fortify their market positions. These strategic partnerships, particularly in the realm of technology-integrated genetic testing, serve to drive innovation, elevate diagnostic capabilities, expand global outreach, ensure adherence to regulatory standards, and propel advancements in personalized medicine. A case in point is the collaboration between Myriad Genetics, a US-based genomic testing company, and Epic Systems, a US-based software company, announced in June 2022. This collaboration focuses on integrating electronic health records (EHR) with genetic testing processes. By seamlessly incorporating Myriad tests into the Epic platform, healthcare providers can efficiently order and review genetic tests, streamlining the overall testing procedure. The integration is designed to improve patient care by delivering crucial genetic insights directly within the electronic health records (EHR) system. Myriad Genetics' strategic emphasis on technology-enabled tools aligns with its growth strategy, with the ultimate goal of enhancing accessibility and efficiency in genetic testing for both patients and clinicians.

In March 2022, LetsGetChecked, a virtual care company based in the United States, specializing in at-home testing, telehealth services, and pharmacy capabilities, successfully acquired Veritas Genetics for an undisclosed sum. This strategic acquisition positions LetsGetChecked to leverage whole-genome sequencing, enabling the initiation of a comprehensive lifecycle of personalized healthcare. The goal is to offer the market an extensive spectrum of health testing and care options. Veritas Genetics, the acquired company, is a biotechnology firm based in the United States, specializing in personal genomics.

Major companies operating in the direct-to-consumer (dtc) genetic testing market report are Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Konica Minolta, Inc., Genesis HealthCare, Inc., Ancestry.com LLC, Myriad Genetics, Inc., Fulgent Genetics, Inc., Sonora Quest Laboratories LLC, Prenetics Limited, 23andMe Holding Co., Color Health Inc., Living DNA Limited, MyHeritage Ltd., Victorian Clinical Genetics Services, Dante Labs S.r.l., Helix OpCo LLC, Gene by Gene, Ltd., Gene by Gene, Ltd., EasyDNA Ltd., Pathway Genomics Corporation, Full Genomes Corporation, Identigene LLC, Mapmygenome Labs Pvt. Ltd., Positive Bioscience Inc., Xcode Life Sciences Private Limited, 24Genetics S.L., Direct Laboratory Services, LLC, Karmagenes SA, Request A Test Ltd., Any Lab Test Now, LLC.

North America was the largest region in the direct-to-consumer (DTC) genetic testing market share in 2023. Asia-Pacific was the second-largest region in the global direct-to-consumer (DTC) genetic testing market. The regions covered in the direct-to-consumer (dtc) genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the direct-to-consumer (dtc) genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Direct-to-consumer (DTC) genetic testing encompasses various types, including carrier testing, predictive testing, ancestry and relationship testing, nutrigenomic testing, and other variants. Carrier screening assesses whether a person carries genetic alterations for specific disorders. These tests analyze saliva, urine, and blood samples using technologies such as single nucleotide polymorphism chips, whole genome sequencing, and targeted analysis. DTC genetic testing operates under different business models such as health planning, comprehensive genome tests, medical precision tests, and restricted trait tests. End-users of these tests include laboratories, blood banks, nursing homes, hospitals, imaging centers, home care, cosmetics, and other sectors.

The direct-to-consumer (DTC) genetic testing market research report is one of a series of new reports that provides direct-to-consumer (DTC) genetic testing market statistics, including direct-to-consumer (DTC) genetic testing industry global market size, regional shares, competitors with a direct-to-consumer (DTC) genetic testing market share, detailed direct-to-consumer (DTC) genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the direct-to-consumer (DTC) genetic testing industry. This direct-to-consumer (DTC) genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The direct-to-consumer (DTC) genetic testing market includes revenues earned by entities by offering DTC genetic kits and services straight to end-customers, that are used in querying patients' DNA information. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.